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NUCLEIC ACIDS ENCODING SARCOC YSTIS
NE URONA ANTIGEN AND USES THEREOF

estimated to be beloW 1% (MacKay et al., 2000), indicating
that there is a clear dichotomy betWeen simple infection With
S. neurona and the occurrence of neurologic disease. In

addition, early attempts at inducing disease by challenging

The present application claims the bene?t of priority of
US. provisional patent application No. 60/357,479 ?led
Feb. 15, 2002.

horses With S. neurona sporocysts gave inconsistent results,
and these studies Were unable to authentically reproduce

acute EPM (Cutler et al., 2001; Fenger et al., 1997). Con
FIELD OF THE INVENTION

sequently, it is apparent that other factors in addition to

The present Invention relates to nucleic acids of Sarco
cyslis neurona. In particular, the present invention relates to
nucleic acids of Sarcocyslis neurona and to nucleic acid
reagents and antibodies for use in methods of detection and

to disease. It is Well established that a robust cell-mediated

prevention of Sarcocyslis neurona infection. More particu
larly, the present invention relates to novel nucleic acid

rona (Dubey et al., 2001a; Marsh et al., 1997), and it is
possible that susceptibility to EPM may be increased in

simple parasite infection are responsible for the progression
immune response is important for controlling infections by
coccidian parasites (Alexander et al., 1997; BasZler et al.,
1999; Krahenbuhl and Remington, 1982), including S. neu

sequences of Sarcocyslis neurona and to utiliZation thereof

horses With inappropriate and/or suppressed immune

including primers, probes, antigen/antibody diagnostic kits,

responses during S. neurona infection. Accordingly, the use
of stress to induce a transient immunosuppression has been

vectors for production of peptides encoding the novel
nucleic acids, and to antigenic proteins and vaccines against
Sarcocyslis neurona.

20

shoWn to provide some improvement to the equine challenge
model for EPM (Saville et al., 2001).
De?nitive antemortem diagnosis of EPM remains exceed
ingly dif?cult, for a variety of reasons. Horses a?licted With

BACKGROUND OF THE INVENTION

EPM exhibit signs that are similar to a number of different

Sarcocyslis neurona is an apicomplexan parasite that is

the primary cause of equine protoZoal myeloencephalitis
(EPM). Due to several factors, de?nitive pre-mortem diag
nosis of EPM remains exceedingly difficult. In particular, the
seroprevalence of S. neurona in horses is signi?cant, yet the
true incidence of EPM is quite loW, thus indicating that
infection does not equate With disease. Additionally, the
immunoblot remains the only commercial assay available

neurological disorders (MacKay et al., 2000). Furthermore,
25

EPM; as a consequence, the detection of anti-S. neurona

30

opment of this test Was a signi?cant advance, it is a

decade-old, ?rst-generation assay that needs to be sup
35

EPM is a common and debilitating infectious disease that
affects the central nervous system of horses. The ?rst

detailed description of the disease Was published in 1970
(Rooney et al., 1970), but it Was not until 1991 that the
etiological agent of EPM Was isolated and designated S.
neurona (Dubey et al., 1991). S. neurona is related to the

antibodies in serum provides little diagnostic information
other than previous exposure to the parasite. Analysis of
cerebrospinal ?uid (CSF) to reveal intrathecal antibody

production, thus suggesting CNS infection, has improved
the predictive value of antibody detection for EPM diagno

for testing samples from suspect EPM horses; While devel

planted.

S. neurona infection does not equate to disease, since only
a small proportion of seropositive horses Will suffer from

sis. HoWever, interpretation of CSF antibody presence can
be confounded by contamination of the CSF sample With
minute amounts of serum antibodies (Miller et al., 1999),
and it is becoming apparent that the presence of antibodies
in the CSF is not a de?nitive indication of active disease.

Additionally, the contemporary diagnostic assays are ham

pered by several intrinsic problems, and they provide only
40

mediocre predictive value for EPM diagnosis. Western blot
analysis (a.k.a., immunoblot) of crude S. neurona lysate

human and animal pathogen Toxoplasma gondii and to the

remains the immunodiagnostic test that is used to detect

important veterinary pathogen Neospora spp. These species

antibodies in suspect EPM horses (Granstrom et al., 1993).

are phylogenetically classi?ed into the Coccidia, Which are

all obligate intracellular parasites that produce a resistant
oocyst during groWth in the intestinal epithelium of their
de?nitive host. Similar to other species of Sarcocyslis, S.

The continued use of the immunoblot has been necessitated
45

by perceived antigenic cross-reactivity betWeen different

50

species of Sarcocyslis, and the assay relies on the recogni
tion of several antigens, primarily in the loW molecular
Weight range, by serum/CSF antibodies (Dubey et al.,
2001b; Granstrom et al., 1993; MacKay et al., 2000). Recent
attempts to improve the immunoblot test have included the
use of antibodies against the related parasite Sarcocyslis
cruzi to block cross-reactive epitopes, theoretically increas
ing the speci?city of the immunoblot analysis for anti-S.
neurona antibodies (Rossano et al., 2000). Unfortunately,

55

Western blot analysis is primarily a research tool that is

neurona has an obligatory heteroxenous life cycle, With the
opossum (Didelphis virginiana) serving as a de?nitive host

(Fenger et al., 1995). The intermediate host(s) include
skunks (Cheadle et al., 2001b), raccoons (Dubey et al.,
2001c), armadillos (Cheadle et al., 2001a), and cats (Dubey
et al., 2000), although felids may be only an experimental
intermediate host that does not contribute to the parasite life
cycle in nature. Horses become infected With S. neurona by
ingesting sporocysts in feces from the opossum, but unlike
the normal intermediate hosts, mature sarcocysts have not

relatively laborious and someWhat hindered by subjectivity,
so any improvements to the immunoblot are of limited
value. While the immunoblot has been utiliZed for a number

been found in equine tissues (MacKay et al., 2000); conse
quently, the horse is currently considered an aberrant dead
end host. The geographic range of S. neurona appears to be

60

limited to the Western Hemisphere, thus EPM primarily
affects horses in the Americas.
Recent seroprevalence studies found that a signi?cant

appropriate for diagnostic use. Nucleic acid ampli?cation
assays (polymerase chain reaction; PCR) for S. neurona

proportion (45% to 55%) of horses have antibodies against
S. neurona (BentZ et al., 1997; Blythe et al., 1997; Saville et

al., 1997), suggesting that these animals are commonly
exposed to the parasite. HoWever, the incidence of EPM is

of years to help diagnose EPM, it is a ?rst-generation test
that needs to be replaced With improved assays based on
simpli?ed, and thus more reliable, techniques that are more
detection have been developed based on the S. neurona

65

ribosomal RNA genes (Fenger et al., 1994; Marsh et al.,
1996). These PCR-based assays detect the presence of S.
neurona DNA, and therefore the parasite, in the horse, so
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they can provide a de?nitive indication of active infection.

means for assessing the nature of the immune response (i.e.,
Thl versus Th2) in S. neurona-infected and EPM horses.
The selection of an antigen for development of a diagnostic
test can be someWhat subjective since any particular patho

However, prior to the present invention, these nucleic acid
based tests have been inherently unreliable. Speci?cally,
parasites may be very feW or non-existent in a CSF sample,

so there Will be no target molecules (i.e., parasite genomic

gen is composed of numerous antigenic proteins. Logically,

DNA) for PCR ampli?cation. More importantly, the general

the target molecule in a diagnostic assay must unfailingly
elicit a detectable antibody response in the infected animal.
A number of previous studies have demonstrated that sur
face antigens of the Coccidia are exceedingly immunogenic.

use of PCR for diagnosis is still suspect; although measures

can be taken to improve the reliability of PCR, the technique
continues to be troubled by both false positive and false

negative results.
Research efforts directed toWard understanding immunity

In particular, the primary surface antigens of Toxoplasma
gondii (Handman and Remington, 1980; Sharma et al.,
1983) and Neaspora caninum (HoWe et al., 1998) have been

against S. neurona infection and improving EPM diagnosis
have been someWhat hampered by the lack of molecular

shoWn to be immunodominant. These surface antigens,

designated SAGs and SAG-related sequences (SRSs), have
been implicated in host cell attachment and invasion by the

information for S. neurona. The identi?cation of S. neurona

speci?c antigens and characterization of the genes encoding
these antigens as provided by the present invention hereby
alloW for the production of recombinant parasite antigens
via expression in E. coli and the subsequent generation of
monoclonal and monospeci?c polyclonal antibodies against
the individual S. neurona antigens. The recombinant pro

parasite (Dzierszinski et al., 2000; GrimWood and Smith,
1992; Hemphill, 1996; Mineo and Kasper, 1994; Mineo et
al., 1993), most likely through interactions With sulfated
20

teins and speci?c antibodies provided by the invention serve
as valuable reagents for conducting immunological studies

surface antigens are involved in modulation of the host

on S. neurona infections and the progression to EPM.

Additionally, these reagents alloW for the development of
neW and more reliable diagnostic tests; for example, a

recombinant S. neurona antigen fumishes the key compo
nent for a simple and ef?cient enzyme-linked immunosor
bent assay (ELISA) that can be used to monitor speci?c
antibodies in equine serum or CSF. As provided by the
teachings herein, the development of an ELISA that is based

25

of N. caninum has been used to develop an ELISA for

Collectively, these previous studies demonstrate that coc
30

that signi?cantly improves current methodologies for iden
35

invention utilizes recombinant S. neurona SAGs that are

provided by the invention to provide simple and reliable
40

45

(1992). Eschenbacher discloses the cloning and expression
of a surface coat protein of Sarcocyslis muris merozoites
consisting of 280 amino acids With a predicted size of 31
kDa.
Velge-Roussel F. et al. “Intranasal Immunization With

55

NALT and GALT compartments. Infection and Immunity,
2000, 68: 969*972, discloses that intra-nasal immunization
With a SAGl protein derived from Toxoplasma gondii plus
a cholera toxin provides protective immunity in mice. Spe

60

compartments after in. immunization. T gondii naturally

Toxoplasma gondii SAGl induces protective cells into both

immune response that is skeWed toWards a Th1 pro?le Will

be characterized by IgG2a and IgG3 (Finkelman et al., 1990;
Snapper et al., 1997). It is generally believed that a Th1

ci?c cellular response Was achieved in nasal and mesenteric

parasites (Alexander et al., 1997; Krahenbuhl and Reming
ton, 1982), so the role of antibody class sWitching for
protection against S. neurona infection is unclear but may be
secondary or unimportant. HoWever, since the antibody
isotypes produced during an infection Will vary depending
on the immune response that has been elicited, monitoring
the relative levels of the speci?c isotypes Will provide a

diagnosis of EPM infection in horses.
Nucleic acids of certain Sarcocyslis and Toxoplasma
species are knoWn in the art. For example, Eschenbacher
K-H et al. “Cloning and expression in Escherichia coli of
cDNAs encoding a 3l-kilodalton surface antigen of Sarco
cyslis muris”. Molec. Biochem. Parasitol. 1992, 53zl59il68

50

the speci?c antibody isotype produced is largely controlled

cell-mediated response is necessary for control of coccidian

ELISAs, and these assays can be used to scrutinize speci?c
humoral immune responses in EPM horses and for detecting
the presence of S. neurona in a test sample. Importantly, the
developed ELISAs are valuable as tools to aid in the

cells and mechanisms. Immunoglobulin isotype sWitching is

by the cytokines associated With the Th1 and Th2 balance
(Finkelman et al., 1990). For example, in the mouse, a
perturbation to the host that stimulates the immune system
predominantly in the Th2 direction Will generate an antibody
response that is characterized by IgE and IgGl, Whereas an

examining immune responses in infected horses and for

developing improved assays for EPM diagnosis. The present

an important immune mechanism that alloWs the host to

generate functional diversity in the humoral response, and

cidian SAGs are at least candidate proteins for the devel

opment of both diagnostic assays and protective vaccines.
Prior to the present invention, hoWever, it had not been
shoWn that the surface antigens of S. neurona (i.e., SnSAG2,
SnSAG3, and SnSAG4) are effective target molecules for

on a single recombinant S. neurona antigen rather than

ply exposed to the parasite versus horses that are actively
infected and suffering from EPM.
A ?uctuating equilibrium is maintained betWeen the cell
mediated and the humoral (antibody) responses of the ver
tebrate immune system, and this balance Will become
biased, depending on the immune stimulus, in an effort to
optimize the protective response. The tWo arms of the
immune system are characterized by Thl or Th2 lympho
cytes that differ in their pro?le of secreted cytokines, and
these immune factors target and regulate different effector

immune response (Lekutis et al., 2001). Signi?cantly, the
TgSAGl surface antigen of T gondii has been shoWn to
protect mice against acute toxoplasmosis (BuloW and Boo
throyd, 1991), and the NcSAGl (p29) major surface antigen
detection of Neospora infection in cattle (HoWe et al., 2002).

Whole-parasite lysate provides a second-generation assay
tifying S. neurona-infected animals. Notably, the use of a
single antigen ELISA Will alloW for a more in-depth and
complete dissection of antibody responses to S. neurona,
Which may distinguish betWeen horses that have been sim

proteoglycans on the host cell surface (He et al., 2002;
Jacquet et al., 2001). In addition to their probable role as
adhesins, there is increasing evidence that some of these

invading the intestine of its host, in this case the mouse, and
can be partially controlled by in. immunization With the

protein SAGl plus CT.
Nielsen et al. discloses the construction of a DNA vaccine
65

using the recombinant form of the surface coat protein

SAGl in Toxoplasma gondii, consisting of 824-nucleotides
encoding the 275 amino acid protein. Animals immunized

US 7,056,733 B2
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With this plasmid produce anti-SAG1 antibodies Which

immunization of sWine against acute sarcocystosis using

recognize the native SAG1. See, Nielsen H. V et al. “Com

in mice immunized With a plasmid encoding the SAG1

cystozooite-derived vaccines”. Vet. Immunol Immuno
pathol. 1985 January;8(1*2):83*92; BuloW R and Boo
throyd J. C. “Protection of mice from fatal Toxoplasma

gene”. Infection and Immunity, 1999, 67: 6358*6363.

gondii infection by immunization With p30 antigen in lipo

plete protection against lethal Toxoplasma gondii infection

somes”. J. Immunol. 1991, 147 3496*3500; Dame J B,
MacKay R J, YoWell C A, Cutler T J, Marsh A, Greiner E C
“S. falcalula from passerine and psittacine birds: synonymy

Peterson et al. discloses the use of an E. coli produced

vaccine comprised of a recombinant Toxoplasma gondii
SAG1 With alum as adjuvant, protecting mice against infec
tion With T gondii. Immunization With E. coli expressing

With S. neurona, agent of EPM”. J. Parasitol. 1995, Decem

ber; 81(6):930*5; Mishima M, Xuan X, Shioda A, Omata Y,
Fujisaki K, NagasaWa H, Mikami T. “Modi?ed protection
against Toxoplasma gondii lethal infection and brain cyst

rSAG1 in alum induced partial protective immunity against
lethal infection With T gondii in mice. See, Petersen E,
Nielsen H V, Christiansen L, Spenter J. Immunization With
E. coli produced recombinant T gondii SAG1 With alum as
adjuvant protect mice against lethal infection with Tom

formation by vaccination With SAG2 and SRS1”. J Vet Med

Sci. 2001 April;63(4):433*8; Aosai F, Mun H S, Norose K,
Chen M, Hata H, Kobayashi M, Kiuchi M, Stauss H J, Yano
A. “Protective immunity induced by vaccination With SAG1

plasma gondii. Vaccine. 1998 August;16(13):1283*9.
Bonenfant et al. discloses intranasal immunity With SAG1
and nontoxic mutant heat-labile enterotoxins protecting

gene-transfected cells against Toxoplasma gondii infection

mice against Toxoplasma gondii. High level protection Was
assessed by the decreased load of cerebral cysts after chal
lenge With the 76H strain of T gondii from a group of mice
immunized With LTR 72 plus SAG1 and LTK63 plus SAG1.

20

(Vulpes vulpes) against rabies”. Vet Rec.1997, Jan. 18,140
(3):57*9; Follmann E H, Ritter D G, Baer G M. “Evaluation
of the safety of tWo attenuated oral rabies vaccines, SAG1
and SAG2, in six Arctic mammals”. Vaccine. 1996 March;

See, Bonenfant C, Dimier-Poisson I, Velge-Roussel F,
Buzoni-Gatel D, Del Giudice G, Rappuoli R, Bout D.
“Intranasal immunization With SAG1 and nontoxic mutant

heat-labile enterotoxins protects mice against Toxoplasma
gondii”. Infect Immun. 2001 March;69(3):1605*12.

25

14(4):270*3; and Windeck T, Gross U.” Toxoplasma gondii
strain-speci?c transcript levels of SAG1 and their associa
tion With virulence”. Parasitol Res. 1996;82(8):715*9.
Yet, despite the foregoing art, there remains a need in the

Haumont et al. discloses that a recombinant form of

Toxoplasma gondii SAG1 used in vaccination had a signi?
cant protective effect against maternofetal transmission of
tachyzoites. Absence of parasites in fetuses Was demon
strated in 66*86% of fetuses from adult guinea pigs. There

in mice”. Microbiol Immunol. 1999;43(1):87*91; Artois M,
Cliquet F, Barrat J, Schumacher C L. “Effectiveness of
SAG1 oral vaccine for the long-term protection of red foxes

art for a safe and effective vaccine against Sarcocyslis
30

neurona. Likewise, as set forth above there is also a need in

the art for diagnostic kits including antigen and antibody kits
for fast and reliable diagnosis of Sarcocyslis neurona infec

Was no quantitative correlation betWeen anti-SAG1 antibody

tion.

titers and protection against maternofetal transmission. This
is reference also demonstrates that a subunit vaccine based

on SAG1 confers a high degree of protection against con

35

OBJECTS OF THE INVENTION

genital T gondii infection. Haumont M, Delhaye L, Garcia
L, Jurado M, Mazzu P, Daminet V, Verlant V, Bollen A,
Beaumans R, Jacquet A. “Protective immunity against con

It is an object of the present invention to satisfy the need
in the art by providing a novel isolated nucleic acid capable

genital toxoplasmosis With recombinant SAG1 protein in a
guinea pig model”. Infect Immun. 2000 September;68(9):

neurona, or unique antigenic fragments thereof. It is also an

4948*53.
Angus et al. discloses that immunization With a DNA

object of the present invention to provide puri?ed antigenic
polypeptide fragments encoded by the novel nucleic acid

plasmid encoding the SAG1 (p30) protein of Toxoplasma

sequences set forth herein that encode for Sarcocyslis neu
rona. In particular, it is an object of the present invention to

gondii is immunogenic and protective in mice. Sera of
immunized mice shoWed recognition of T gondii tachyzoi
tes by immuno?uorescence and exhibited high titers of
antibody to SAG1 by ELISA. This data suggest that nucleic
acid vaccination can provide protection against T gondii
infection in mice. See, Angus C W, Klivington-Evans D,
Dubey J P, Kovacs J A.” Immunization With a DNA plasmid

of encoding antigenic proteins derived from Sarcocyslis

45

portion thereof, in a pharmaceutically acceptable carrier.
It is further an object of the present invention to provide
50

encoding the SAG1 (P30) protein of Toxoplasma gondii is

January;181(1):317*24.
cally inactivated and incorporates an adjuvant is used as an
EPM vaccine. This vaccine has been conditionally licensed
for use but Without any indication of its effectiveness in

1998, 29 (34):289*310; O,Donoghue P J et al. “Attempted

Another object of the invention is to provide a vector
comprising the nucleic acid encoding Sarcocyslis neurona or
a unique fragment thereof and to provide the vector in a host

capable of expressing the polypeptide encoded by that
60

nucleic acid.
One important object of the invention is to provide a

puri?ed antibody that is selectively reactive With Sarcocyslis
neurona or an immunodominant polypeptide provided by
the invention or a genetic variant thereof. A particular object
of the present invention is to provide a puri?ed monoclonal

Dodge Animal Health, 20001.
Other references of interest includezBuxton D. “Protozoan
infections in sheep and goats: recent advances” Vet. Res.

the nucleic acid from Sarcocyslis neurona including, but not

techniques.
55

closes that an S. neurona merozoite culture that is chemi

preventing Sarcocysl neurona induced EPM Fort Dodge
Animal Health, “Vaccine Development” Discloses that an S.
neurona merozoite culture that is chemically inactivated and
incorporates an adjuvant is used as the EPM vaccine. Fort

isolated nucleic acids capable of selectively hybridizing With
limited to, primers and probes for utilization in polymerase
chain reaction (PCR) and other nucleic acid ampli?cation

immunogenic and protective in rodents”. J Infect Dis. 2000

Fort Dodge Animal Health, “Vaccine Development” dis

provide a puri?ed antigenic polypeptide fragment encoded
by the nucleic acid sequences set forth herein or a selective

65

antibody speci?cally reactive With Sarcocyslis neurona and
a method of detection of Sarcocyslis neurona utilizing the
antibodies of the present invention.

US 7,056,733 B2
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SUMMARY OF THE INVENTION

against the recombinant proteins. Western blot analysis of
reduced antigen revealed that each SnSAG migrated signi?
cantly higher than its predicted molecular Weight, consistent

The present invention satis?es the need in the art by
providing a novel isolated nucleic acid encoding an anti
genic protein derived from Sarcocyslis neurona, or a unique
fragment thereof. In one embodiment, the invention pro

With What has been observed for the T gondii SAGs/SRS.
SnSAGl and SnSAG4 co-migrated and corresponded to the

vides novel isolated nucleic acids encoding membrane
associated polypeptides SnSAG2, SnSAG3, and SnSAG 4.

responded to an immunodominant band at approximately
l8*20 kDa.

The present invention also provides puri?ed antigenic
polypeptide fragments encoded by the novel nucleic acid

Sarcocyslis neurona meroZites. Triton X-ll4 partitioning

sequences set forth herein that encode for Sarcocyslis neu
rona. In one embodiment, the invention provides puri?ed

branes, consistent With their surface localiZation via gly

immunodominant band at about 30*32 kDa. SnSAG2 cor

FIG. 4 shoWs the SnSAGs are membrane-associated in
assays indicated that the SnSAGs are associated With mem

antigenic proteins or puri?ed antigenic polypeptide frag

colipid anchoring. Western blot analysis of the partitioned
proteins With the SnSAG-speci?c polyclonal antisera

ments encoded by the novel nucleic acid sequences set forth
herein that encode for SnSAG2, SnSAG3, and SnSAG 4. In

revealed that all four SnSAGs Were separated exclusively

another embodiment, the present invention provides a puri

into the detergent phase (D). The control protein, SnMIClO,

?ed antigenic polypeptide fragment encoded by the nucleic

Was partitioned into the aqueous phase (A), as expected.
FIG. 5 shoWs that the four SnSAGs are displayed on the

acid sequences set forth herein or a selective portion thereof,

in a pharmaceutically acceptable carrier.
The present invention also provides isolated nucleic acids
capable of selectively hybridizing With the nucleic acid from
Sarcocyslis neurona including, but not limited to, primers
and probes for utiliZation in polymerase chain reaction

(PCR) and other nucleic acid ampli?cation techniques.
Further, the present invention provides vectors compris

surface of Sarcocyslis neurona meroZoites. Surface biotiny
20

ern blot analysis With the SnSAG-speci?c antisera revealed
each of the SnSAGs in the biotinylated protein fraction

precipitated With immobiliZed streptavidin. The SnSAGs
25

ing the isolated nucleic acids set forth herein encoding
Sarcocyslis neurona or a unique fragment thereof and pro

vides the vector in a host capable of expressing the polypep
tide encoded by that nucleic acid.
Finally, the present invention also provides a puri?ed

lation of S. neurona meroZoites indicated that the four
SnSAGs are displayed on the surface of the parasite. West

Were not present in the non-labeled parasites, thus indicating
that the streptavidin precipitation Were speci?c for biotin
labeled proteins. The negative control protein (actin) Was not
detected in the biotin-labeled/streptavidin-precipitated pro
tein fraction.

30

DETAILED DESCRIPTION OF THE
INVENTION

polyclonal and or a monoclonal antibody speci?cally reac
tive With Sarcocystis neurona and a method of detection of

Sarcocyslis neurona utiliZing the antibodies of the present
invention.
35

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention may be understood more readily by
reference to the folloWing detailed description of speci?c
embodiments and the examples included therein. As used in
the claims, “a” can mean one or more. As can be appreciated

FIG. 1 is a sequence comparison of mature SnSAGl (SEQ

ID NO.:31), SnSAG4 (SEQ ID NO.: 32), and SnSAG3
(SEQ ID NO.: 33) With SmMSA (SEQ ID NO.: 34) and
TgSAG2E (SEQ ID NO.:35). The S. neurona surface anti

by one of skill in the art, methods and materials similar or
equivalent to those described herein can be used in the
40

gens SnSAGl, SnSAG3 and SnSAG4 are most similar to the

practice of the present invention. All publications, patent
applications, patents, and other references mentioned herein
are incorporated by reference in their entirety. The disclo

TgSAG2 family of T gondi surface antigens. The sequences

sures of these publications in their entireties are hereby

presented in the Figure are for the mature proteins after

incorporated by reference into this application in order to

cleaving off the N-terminal signal peptide and the C-termi
nal signal for the GPI anchor. Sequence alignments of the
predicted mature proteins revealed very moderate sequence
identity (<25%). HoWever, the SnSAGs contain 10/12 con
served cysteine residues that have been observed previously,

45

suggesting that the SnSAGs have a tertiary structure that is
similar to What has been determined for the TgSAGs/SRSs.
FIG. 2 is a sequence comparison of mature SnSAG2 (SEQ

50

invention pertains. Although the present invention has been
described With reference to speci?c details of certain
embodiments thereof, it is not intended that such details
should be regarded as limitations upon the scope of the

de?nitions Will control. In addition, the particular embodi
ments discussed beloW are illustrative only and not intended
55

signal peptide and the C-terminal signal for the GPI anchor.
The S. neurona surface antigen SnSAG2 is most similar to

the TgSAGl family of T gondii surface antigens. Similar to
60

E. coli, and monospeci?c polyclonal antisera Were generated

As used herein, a “nucleic acid” means a chain of at least
tWo or more nucleotides such as DNA (deoxyribonucleic

acid) or RNA (ribonucleic acid). As used herein, a “puri?ed”
nucleic acid is one that is substantially separated from other

TgSAGs.
FIG. 3 shoWs a Western blot analysis of the Sn SAGs in
S. neurona meroZoites. The SnSAG genes Were expressed in

to be limiting.
The present invention satis?es the long felt need in the art
by providing novel isolated nucleic acid sequences Which

encode antigenic proteins derived from Sarcocyslis neurona,
or Which encode unique antigenic protein fragments thereof.

the other SnSAGs, SnSAG2 shares modest sequence iden

tity to its TgSAG orthologues, but contains 6/6 conserved
cysteine residues that have been observed in each half of the
prototypical tWo-domain apicomplexan SAG. SnSAG2 Will
also align With the carboxyl-terminal domain of the

invention except as and to the extent that they are included
in the accompanying claims. In the case of a con?ict With

incorporated references, the present speci?cation, including

ID NO.: 36) With TgSAGl (SEQ ID NO.: 37) and TgSRS2
(SEQ ID NO.: 38). The sequences presented in the Figure
are for the mature proteins after cleaving off the N-terminal

more fully describe the state of the art to Which this

nucleic acid sequences in a cell or organism in Which the
65

nucleic acid naturally occurs. Likewise, by “isolated”
nucleic acid is meant separated from at least some of other

nucleic acids found in the naturally-occurring organism. The

US 7,056,733 B2
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nucleic acids of the present invention can include positive

life-style. Parasite surface molecules are virulence factors

and negative strand RNA as Well as DNA. The above terms

that are typically novel and undoubtedly important since
they are responsible for the initial interactions With the host
cell surface and host immune response. In Toxoplasma
gondii for example, an extensive family of 25+ surface
antigens has been identi?ed, Which are developmentally
regulated and exhibit various levels of sequence similarity to

encompass double-stranded DNA, single-stranded DNA,
and RNA and are meant to include genomic and subgenomic

nucleic acids found in the naturally-occurring Sarcocyslis
neurona organism. The nucleic acids contemplated by the
present invention include a nucleic acid having sequences
from Which a Sarcocyslis neurona cDNA can be transcribed;

either of the major T gondii surface antigens TgSAG1 or

or allelic variants and/or homologs of thereof. By “capable
of selectively hybridizing” is meant a sequence Which does
not hybridize With other nucleic acids to prevent an adequate

TgSAG2. These surface molecules appear to be involved in

receptor/ligand interactions With the host cell surface, and
there is increasing evidence that some of the T gondii SAGs

positive hybridization With nucleic acids from Sarcocyslis

are involved in modulation of host immune responses.

neurona and is meant to include stringent hybridization

In one embodiment, the present invention provides iden
tity and characterization of certain of the virulence factors of
S. neurona. In particular, the present invention provides four
isolated nucleic acids of S. neurona (genes) that encode
parasitic surface antigens. A sequencing project Was con

conditions including loW, moderate and high stringency
conditions. Such stringency conditions are knoWn in the
artas, e.g., in US. Patent Publication No.: 2002/0115828A1.

By “unique fragment” is meant a fragment of the nucleic
acids set forth in the Sequence Listing that is less than the
full length that can selectively hybridize With a RNA, DNA
or cDNA sequence derived from the novel sequences set

ducted that generated approximately 8500 expressed
sequence tags (ESTs) from this organism. Examination of
20

forth herein or that can selectively hybridize With nucleic
acids from Sarcocyslis neurona. Modi?cations to the nucleic
acids of the invention are also contemplated as long as the
essential structure and function of the polypeptide encoded

by the nucleic acids is maintained. Likewise, fragments used

this sequence database has revealed a family of at least four
S. neurona surface antigens that are orthologues of the

SAG/SRS family of surface proteins in T gondii. Based on
their homology to the T gondii SAGs, the novel S. neurona
25

surface antigens have been designated SnSAGl, SnSAG2,
SnSAG3, and SnSAG4 respectively. Each protein is pre

as primers or probes can have substitutions so long as

dicted to contain an amino-terminal signal peptide and a

enough complementary bases exist for selective hybridiza

carboxyl-terminal glycolipid anchor addition site, indicating

tion (Kunkel et al. Methods Enzmol. 1987: 1544367, 1987).

surface localization, and Triton X-114 partitioning and sur
face biotinylation assays con?rmed that all four proteins are

As one of skill in the art can appreciate, there can be

naturally occurring allelic variants and non-naturally occur

30

invention. For example, homologs or naturally occurring
allelic variants of the nucleic acids of the invention having
from about 50% and up to about 99% sequence identity are

contemplated by the invention. Likewise, it is contemplated

35

that non-naturally occurring variants or modi?cations of the
nucleic acids of the invention can range from about 50% to
about 99% sequence identity to native S. neurona are

Accordingly, one embodiment of the present invention
40

provides isolated nucleic acid derived from three Sarcocyslis

neurona Which encodes a 276 amino acid polypeptide set
45

forth in the Sequence Listing as SEQ ID NO: 22. The
polypeptide encoded by SEQ ID NO: 22 has a predicted

amino-terminal signal peptide (indicating expression via the
secretory pathWay) and a glycolipid anchor addition site at

three Sarcocyslis neurona cluster sequences. The polypep
tide sequence comprising Sn Cluster 144 is set forth in the

Sequence Listing as SEQ ID NO: 2. The polypeptide

comprises an isolated nucleic acid as set forth in the

Sequence listing as SEQ ID NO: 21. The nucleic acid
identi?ed in SEQ ID NO: 21 comprises an 828-nucleotide
open reading frame of the SnSAGl gene of Sarcocyslis

neurona cluster sequences, namely Sn Cluster 144, Sn
Cluster 21 and Sn Cluster 4, Which comprise the nucleotide
sequences set forth in the Sequence Listing as SEQ ID NOS:

1, 3, and 29 respectively and the sequences complimentary
thereto. Also provided by the invention are the correspond
ing protein or polypeptide amino acid sequences for these

SAGs and Which are likely important for the tertiary struc
ture of the proteins (See, FIGS. 1 and 2). Due to their surface
localization and relative homology to T gondii surface
antigens, these S. neurona proteins have been designated

SnSAGl, SnSAG2, SnSAG3, and SnSAG4.

contemplated.
In particular, one embodiment of the present invention

membrane-associated and displayed on the S. neurona mero

zoite surface (See, FIGS. 4 and 5). Additionally, these novel
S. neurona proteins possess multiple conserved cysteine
residues that have been described previously for T gondii

ring variants or modi?cations of the nucleic acids of the

the carboxy-terminal end (indicating surface localization).
50

Database searches With the predicted protein sequence of

sequence comprising Sn Cluster 21 is set forth in the

SnSAGl (rSnSAGl) revealed signi?cant similarity (align

Sequence Listing as SEQ ID NO: 4 and the polypeptide

ment score:80, E value:2><10*14) to a 31 kDa surface

sequence comprising Sn Cluster 4 is set forth in the
Sequence Listing as SEQ ID NO: 30. As used herein, the
terms “polypeptide” and “protein” are used interchangeably

antigen from Sarcocyslis muris.
A recombinant form of the Sarcocyslis neurona SnSAGl
55

and are meant to include any peptide-linked chain of amino

acids, regardless of length or post-translational modi?cation,
e.g., glycosylation or phosphorylation. By “puri?ed”
polypeptide is meant a polypeptide that has been substan
tially separated or isolated aWay from other polypeptides in
a cell, organism, or mixture in Which the polypeptide occurs.
Sarcocyslis neurona is an apicomplexan parasite that can

60

cause a severe neurologic disease in horses called equine

protozoal myeloencephalitis (EPM). Similar to other mem
bers of the Apicomplexa, S. neurona is an obligate intrac
ellular pathogen that utilizes a number of unique structures

and molecules (i.e., virulence factors) to support its parasitic

65

(rSnSAGl) has been expressed in E. coli. Western blot
analysis of rSnSAG1 demonstrated that the recombinant
antigen is recognized by antiserum from a rabbit that Was
immunized With S. neurona merozoites and by antibodies in
cerebrospinal ?uid (CSF) from an EPM (Sarcocyslis neu
rona infected) horse (See, e.g., FIG. 3).
Another embodiment of the present invention comprises
an isolated nucleic acid as set forth in the Sequence listing
as SEQ ID NO: 23. The nucleic acid identi?ed in SEQ ID
NO: 23 comprises an 975 nucleotide open reading frame of
the SnSAG2 gene of Sarcocyslis neurona Which encodes a

168 amino acid polypeptide set forth in the Sequence Listing
as SEQ ID NO: 24.

US 7,056,733 B2
11

12
Yet another embodiment of the present invention provides

The present invention also provides an isolated nucleic
acid as set forth in the Sequence listing as SEQ ID NO: 25.
The nucleic acid identi?ed in SEQ ID NO: 25 comprises an
1585 nucleotide open reading frame of the SnSAG3 gene of

an isolated nucleic acid designated SnGFlc Which com

prises the nucleic acid set forth in SEQ ID NO: 9 and
sequences complimentary thereto. Another embodiment of

polypeptide set forth in the Sequence Listing as SEQ ID NO:

the invention comprises the polypeptide sequence encoded
by SnGFlc set forth in the Sequence Listing as SEQ ID NO:

26.

10.

Also provided by the present invention is an isolated
nucleic acid as set forth in the Sequence listing as SEQ ID
NO: 27. The nucleic acid identi?ed in SEQ ID NO: 27
comprises an 1111 nucleotide open reading frame of the

Still another embodiment of the present invention pro
vides an isolated nucleic acid designated SnGFld Which
comprises the nucleic acid set forth in SEQ ID NO: 11 and
sequences complimentary thereto. Another embodiment of

SnSAG4 gene of Sarcocyslis neurona Which encodes a 287

the invention comprises the polypeptide sequence encoded
by SnGFld set forth in the Sequence Listing as SEQ ID NO:

Sarcocyslis neurona Which encodes a 281 amino acid

5

amino acid polypeptide set forth in the Sequence Listing as
SEQ ID NO: 28.
As set forth more fully beloW, these genes have been
expressed as recombinant proteins in E. coli. The recombi
nant SnSAG proteins can be implemented into antibody
capture ELISAs and used to detect the presence of S.

12.

The present invention also provides an isolated nucleic

neurona antibodies in a sample. Likewise, the recombinant

proteins provided by the invention can be used as reagents

20

acid designated SnGFle Which comprises the nucleic acid
set forth in SEQ ID NO: 13 and sequences complimentary
thereto. Another embodiment of the invention comprises the
polypeptide sequence encoded by SnGFle set forth in the
Sequence Listing as SEQ ID NO: 14.
Another embodiment of the present invention provides an

for use in vaccines against S. neurona.

Another embodiment of the present invention includes the

isolated nucleic acid designated SnGFlf Which comprises

discovery of additional novel expressed sequence tags (EST)

the nucleic acid set forth in SEQ ID NO: 15 and sequences
complimentary thereto. Another embodiment of the inven

that encode novel antigenic peptides for utiliZation in the
vaccines and diagnostic kits as disclosed by this invention.
In particular, in a presently preferred embodiment of the
invention, cluster analysis of the Sarcocyslis neurona

25

tion comprises the polypeptide sequence encoded by
SnGFlf set forth in the Sequence Listing as SEQ ID NO: 16.
Yet another embodiment of the present invention provides

expressed sequence tags (ESTs) generated from the cSn.1

an isolated nucleic acid designated SnGFl g Which com

cDNA library has revealed a gene family that encodes at

prises the nucleic acid set forth in SEQ ID NO: 17 and
sequences complimentary thereto. Another embodiment of

least eight homologous proteins. Of the approximately 8500

30

the invention comprises the polypeptide sequence encoded
by SnGFl g set forth in the Sequence Listing as SEQ ID NO:

S. neurona ESTs that have been generated thus far, roughly
540 sequences can be placed in this gene family, Which has
been provisionally designated SnGFl (S. neurona Gene
Family 1). Based on its relative abundance in the collection
of S. neurona ESTs, SnGFl encodes a set of similar proteins

18.
35

(at least eight) that are highly expressed and most likely play
signi?cant roles in the biology of S. neurona (i.e., parasite
virulence factors). In addition to their biological importance,
the abundance of these proteins Would suggest that they
elicit signi?cant immune responses in infected animals.
Collectively, the characteristics of the novel nucleic acids of
SnGFl, and the encoded proteins therefrom, make this gene

the invention comprises the polypeptide sequence encoded
by SnGFlh set forth in the Sequence Listing as SEQ ID NO:
40

family Well suited for the development of improved diag
45

proteins of, e.g., 109 amino acids, 106 amino acids, and 107
amino acids in length, and the proteins share approximately

present invention. The vectors can be utiliZed in host expres
50

membrane domain near the C-terminus. The SnGFl mem

bers shoW no similarity to sequences in the current public

gene databases, suggesting that SnGFl is relatively unique

the invention comprises the polypeptide sequence encoded
by SnGFla set forth in the Sequence Listing as SEQ ID NO:

sion systems to produce antigenic peptide reagents for
diagnostic and prophylactic applications. The present inven
tion also provides puri?ed antibodies selectively reactive
With S. neurona. These antibodies can be used in various
diagnostic methods or as a therapeutic.

to S. neurona.

Accordingly, one embodiment of the present invention
provides an isolated nucleic acid designated SnGFla Which
comprises the nucleic acid set forth in SEQ ID NO: 5 and
sequences complimentary thereto. Another embodiment of

derived therefrom Which can be utiliZed to diagnose and
prevent infection of S. neurona. Puri?ed polypeptides
encoded by the nucleic acids are also provided. These
polypeptides can be utiliZed in methods of diagnosis or as
vaccine components for prevention of infection. Vectors are

also provided Which comprise the nucleic acids of the

70% to 80% sequence identity. These proteins have a

predicted N-terminal signal peptide and a predicted trans

20.

The present invention provides isolated nucleic acids as
set forth in the Sequence Listing and nucleic acid reagents

nostics and/or vaccines for EPM as set forth herein.

The eight SnGFl isoforms identi?ed thus far have been
designated SnGFlaih. These genes are predicted to encode

Still another embodiment of the present invention pro
vides an isolated nucleic acid designated SnGFlh Which
comprises the nucleic acid set forth in SEQ ID NO: 19 and
sequences complimentary thereto. Another embodiment of

55

In one embodiment, the invention provides puri?ed anti
genic polypeptides encoded by the nucleic acids set forth in
the Sequence Listing. The invention also provides these

antigenic polypeptides in a pharmaceutically acceptable
60

carrier. The amino acid sequence of these polypeptides can
be deduced from the nucleotide sequences set forth in the

Sequence Listing.

6.

Another embodiment of the present invention provides an

Puri?ed antigenic polypeptide fragments encoded by the

isolated nucleic acid designated SnGFlb Which comprises

nucleic acids of the present invention are also contemplated.
As used herein, “puri?ed” means the antigen is at least
suf?ciently free of contaminants or cell components With

the nucleic acid set forth in SEQ ID NO: 7 and sequences
complimentary thereto. Another embodiment of the inven

65

tion comprises the polypeptide sequence encoded by

Which the antigen normally occurs to distinguish the antigen

SnGFlb set forth in the Sequence Listing as SEQ ID NO: 8.

from the contaminants or components. Puri?ed antigenic

US 7,056,733 B2
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polypeptides of S. neurona and antigenic fragments thereof

fragments contemplated by the present invention. There are

of the present invention are also referred to herein as “the

numerous E. coli expression vectors knoWn to one of

antigen” or “the S. neurona antigen.” It is contemplated that
the antigenic fragments can be encoded from any portion of

the open reading frames set forth in SEQ ID NOS: 24, 26

ordinary skill in the art useful for the expression of the
antigen. Other microbial hosts suitable for use include
bacilli, such as Bacillus sublilis, and other enterobacteri
aceae, such as Salmonella, Serralia, and various Pseudomo
nas species. In these prokaryotic hosts one can also make

the nucleic acid encoding S. neurona as set forth in the

Sequence Listing, but especially from fragments encoded by
and 28 as described herein. Speci?cally, one example pro

expression vectors, Which Will typically contain expression

vides an approximately 12 kDa antigenic polypeptide
encoded by an open reading frame of SEQ ID NO: 24
consisting essentially of the amino acids encoded by the

control sequences compatible With the host cell (e.g., an
origin of replication). In addition, any number of a variety of
Well-known promoters can be present, such as the lactose

nucleotide as sequence set forth in the Sequence Listing as

promoter system, a tryptophan (Trp) promoter system, a

SEQ ID NO: 23.
An antigenic fragment of the antigen can be isolated from
the Whole antigen by chemical or mechanical disruption.
The puri?ed fragments thus obtained can be tested to

beta-lactamase promoter system, or a promoter system from

phage lambda. The promoters Will typically control expres
sion, optionally With an operator sequence, and have ribo
some binding site sequences for example, for initiating and
completing transcription and translation. If necessary, for
example, an amino terminal methionine can be provided by
insertion of a Met codon 5' and in-frame With the antigen.

determine their antigenicity and speci?city by the methods
taught herein. Antigenic fragments of the antigen can also be
synthesiZed directly. An immunoreactive fragment is gen
erally an amino acid sequence of at least about ?ve con

20

Also, the carboxyterminal extension of the antigenic frag

secutive amino acids derived from the antigen amino acid

ments can be removed using standard oligonucleotide

sequence.

mutagenesis procedures.

The polypeptide fragments of the present invention can

also be recombinant proteins obtained by cloning nucleic
acids encoding the polypeptide in an expression system
capable of producing the antigenic polypeptide or fragments

Additionally, yeast expression can be used. There are

several advantages to yeast expression systems. First, evi
25

dence exists that proteins produced in a yeast secretion
systems exhibit correct disul?de pairing. Second, post

translational glycosylation is ef?ciently carried out by yeast

thereof.

Once the amino acid sequence of the antigen is provided,

secretory systems. In one example, the Saccharomyces cer

it is also possible to synthesiZe, using standard peptide
synthesis techniques, peptide fragments chosen to be
homologous to immunoreactive regions of the antigen and to
modify these fragments by inclusion, deletion or modi?ca

evisiae pre-pro-alpha-factor leader region (encoded by the
30

tion of particular amino acids residues in the derived
sequences. Thus, synthesis or puri?cation of an extremely

large number of peptides derived from the antigen is pos
sible.
The amino acid sequences of the present polypeptides can
contain an immunoreactive portion of the S. neurona antigen
attached to sequences designed to provide for some addi
tional property, such as solubility. The amino acid sequences

35

sequence can be fused in-frame to the pre-pro-alpha-factor

40

fused to a second protein coding sequence, such as Sj26 or
45

noreactivity, immunogenicity, etc.
50

of antibodies or cell mediated immunity) of an animal to
55

administered depend on the subject, eg a horse or a guinea

pig, the condition of the subject, the siZe of the subject, etc.
Thereafter an animal so inoculated With the antigen can be

exposed to the parasite to test the potential vaccine effect of

the speci?c immunogenic fragment. The speci?city of a
putative immunogenic fragment can be ascertained by test

60

ing sera, other ?uids or lymphocytes from the inoculated
animal for cross reactivity With other closely related Sarco

A vector comprising the nucleic acids of the present

be in a host capable of expressing the antigenic polypeptide

protease cleavage sites to separate the components of the
fusion protein is applicable to constructs used for expression
in yeast.
Mammalian cells permit the expression of proteins in an
environment that favors important post-translational modi
?cations such as folding and cysteine pairing, addition of
complex carbohydrate structures, and secretion of active
protein. Vectors useful for the expression of antigen in
mammalian cells are characterized by insertion of the anti
gen coding sequence betWeen a strong viral promoter and a
polyadenylation signal. The vectors can contain genes con
ferring either gentamicin or methotrexate resistance for use
as selectable markers. The antigen and immunoreactive
fragment coding sequence can be introduced into a Chinese
hamster ovary cell line using a methotrexate resistance
encoding vector. Presence of the vector DNA in transformed

cells can be con?rmed by Southern analysis and production

cyslis spp.
invention is also provided. The vectors of the invention can

.beta.-galactosidase, used to facilitate puri?cation of the

fusion protein by af?nity chromatography. The insertion of

peptide should posses a bioactive property, such as immu

each concentration is determined. The amounts of antigen

leader region. This construct is then put under the control of
a strong transcription promoter, such as the alcohol dehy
drogenase I promoter or a glycolytic promoter. The antigen
coding sequence is folloWed by a translation termination

codon Which is folloWed by transcription termination sig
nals. Alternatively, the antigen coding sequences can be

amino acid to provide for some additional property, such as

The puri?ed polypeptide fragments thus obtained can be
tested to determine their immunogenicity and speci?city.
Brie?y, various concentrations of a putative immunogeni
cally speci?c fragment are prepared and administered to an
animal and the immunological response (e.g., the production

segment Which includes a recognition sequence for a yeast
protease encoded by the KEX2 gene: this enZyme cleaves
the precursor protein on the carboxyl side of a Lys-Arg

dipeptide cleavage-signal sequence. The antigen coding

of an S. neurona antigen can include sequences in Which one
or more amino acids have been substituted With another

to remove/add amino acids capable of disul?de bonding, to
increase its bio-longevity, alter enZymatic activity, or alter
interactions, e.g., With gastric acidity. In any case, the

MF.alpha.-l gene) is routinely used to direct protein secre
tion from yeast (Brake et al., 1984). The leader region of
pre-pro-alpha-factor contains a signal peptide and a pro

of a cDNA or opposite strand RNA corresponding to the
65

antigen coding sequence can be con?rmed by northern
analysis. A number of other suitable host cell lines capable
of secreting intact proteins have been developed in the art,

US 7,056,733 B2
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and include the CHO cell lines, HeLa cells, myeloma cell

an immortal cell line and screened for antibody secretion.

lines, Jurkat cells, etc. Expression vectors for these cells can
include expression control sequences, such as an origin of
replication, a promoter, an enhancer, and necessary infor

The antibodies can be used to screen clone libraries for cells

mation processing sites, such as ribosome binding sites,

10: 1634167, (1992) and Bebbington et at., Bio/Technology,
10: 1694175, (1992).

secreting the antigen. Those positive clones can then be

sequenced (see, for example, Kelly et al., Bio/Technology,

RNA splice sites, polyadenylation sites, and transcriptional
terminator sequences. Preferred expression control
sequences are promoters derived from immunoglobulin
genes, SV40, Adenovirus, Bovine Papilloma Virus, etc. The

The antibody can be bound to a substrate or labeled With
a detectable moiety or both bound and labeled. The detect

able moieties contemplated by the present invention include,

vectors containing the nucleic acid segments of interest can

but are not limited to ?uorescent, enzymatic and radioactive
markers.

be transferred into the host cell by Well-knoWn methods,
Which vary depending on the type of cellular host. For

A puri?ed S. neurona antigen bound to a substrate and a

example, calcium chloride transfection is commonly utilized
for prokaryotic cells, Whereas calcium phosphate treatment

templated. Such a puri?ed ligand speci?cally reactive With

or electroporation may be used for other celluar hosts.
Alternative vectors for the expression of antigen in mam
malian cells, those similar to those developed for the expres

monoclonal antibody obtained by standard methods and as
described herein. The monoclonal antibody can be secreted

sion of human gammainterferon, tissue plasminogen activa
tor, clotting Factor VIII, hepatitis B virus surface antigen,
protease Nexinl, and eosinophil major basic protein, can be

by a hybridoma cell line speci?cally produced for that
purpose (HarloW and Lane, 1988). Likewise, nonhuman
polyclonal antibodies speci?cally reactive With the antigen

ligand speci?cally reactive With the antigen are also con
the antigen can be an antibody. The antibody can be a

20

are Within the scope of the present invention. The polyclonal
antibody can also be obtained by the standard immunization

employed. Further, the vector can include CMV promoter
sequences and a polyadenylation signal available for expres
sion of inserted nucleic acid in mammalian cells (such as

and puri?cation protocols (HarloW and Lane, 1988).
The present invention provides a method of detecting the

COS7).
The nucleic acid sequences can be expressed in hosts after

25

presence of S. neurona in a subject, comprising the steps of

the sequences have been operably linked to, i.e., positioned

contacting an antibody-containing sample from the subject

to ensure the functioning of, an expression control sequence.

With a detectable mount of the antigenic polypeptide frag
ment of the present invention and detecting the reaction of

These expression vectors are typically replicable in the host
organisms either as episomes or as an integral part of the
host chromosomal DNA. Commonly, expression vectors can

the fragment and the antibody, the reaction indicating the
30

presence of the S. neurona or a previous infection With S.

contain selection markers, e.g., tetracycline resistance or

neurona.

hygromycin resistance, to permit detection and/or selection

One example of the method of detecting S. neurona is
performed by contacting a ?uid or tissue sample from the
subject With an amount of a puri?ed antibody speci?cally
reactive With the antigen as de?ned herein, and detecting the
reaction of the ligand With the antigen. It is contemplated
that the antigen Will be on intact cells containing the antigen,
or Will be fragments of the antigen. As contemplated herein,
the antibody includes any ligand Which binds the antigen, for

of those cells transformed With the desired nucleic acid

sequences (see, e.g., US. Pat. No. 4,704,362).
Polynucleotides encoding a variant polypeptide may
include sequences that facilitate transcription (expression
sequences) and translation of the coding sequences such that

35

the encoded polypeptide product is produced. Construction
of such polynucleotides is Well knoWn in the art. For
example, such polynucleotides can include a promoter, a

40

transcription termination site (polyadenylation site in

example, an intact antibody, a fragment of an antibody or

eukaryotic expression hosts), a ribosome binding site, and,

another reagent that has reactivity With the antigen. The ?uid
sample of this method can comprise any body ?uid Which

optionally, an enhancer for use in eukaryotic expression

Would contain the antigen or a cell containing the antigen,

hosts, and, optionally, sequences necessary for replication of
a vector.

45

One presently preferred vector system for expression of
the peptides of the invention comprises the use of Alphavi

Enzyme immunoassays such as immuno?uorescence
assays (IFA), enzyme linked immunosorbent assays

rus vector constructs, for example, as set forth in US. Pat.

Nos.: 5,643,576; 5,843,723; 6,156,558; and 6,242,259, the
teachings of Which are hereby incorporated herein by ref

50

erence.

A puri?ed monoclonal antibody speci?cally reactive With
S. neurona is also provided. The antibodies can be speci?

cally reactive With a unique epitope of the antigen or they
can also react With epitopes of other organisms. The term
“reactive” means capable of binding or otherWise associat
ing non randomly With an antigen. “Speci?cally reactive” as
used herein refers to an antibody or other ligand that does
not cross react substantially With any antigen other than the

such as blood, plasma, serum, cerebrospinal ?uid, saliva,
feces and urine. Other possible examples of body ?uids
include sputum, mucus, gastric juice and the like.

55

(ELISA) and immunoblotting can be readily adapted to
accomplish the detection of the antigen. An ELISA method
effective for the detection of the antigen can, for example, be
as folloWs: (1) bind the antibody to a substrate; (2) contact
the bound antibody With a ?uid or tissue sample containing
the antigen; (3) contact the above With a secondary antibody
bound to a detectable moiety (e.g., horseradish peroxidase
enzyme or alkaline phosphatase enzyme); (4) contact the
above With the substrate for the enzyme; (5) contact the
above With a color reagent; (6) observe color change. The
above method can be readily modi?ed to detect antibody as

one speci?ed, in this case, S. neurona. Antibodies can be 60 Well as antigen.

Another immunologic technique that can be useful in the

made as described in the Examples (see also, HarloW and

Lane, Antibodies; A Laboratory Manual, Cold Spring Har

detection of S. neurona or previous S. neurona infection

bor Laboratory, Cold Spring Harbor, N.Y., 1988). Brie?y

utilizes monoclonal antibodies (MAbs) for detection of
antibodies speci?cally reactive With S. neurona antigen.
Brie?y, sera or other body ?uids from the subject is reacted

puri?ed antigen can be injected into an animal in an amount
and in intervals su?icient to elicit an immune response.
Antibodies can either be puri?ed directly, or spleen cells can
be obtained from the animal. The cells are then fused With

65

With the antigen bound to a substrate (eg an ELISA 96-Well
plate). Excess sera is thoroughly Washed aWay. A labeled
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(enzyme-linked, ?uorescent, radioactive, etc.) monoclonal

also be potentially cross-reactive With antibodies to other

antibody is then reacted With the previously reacted antigen

antigens. The vaccine can then be used in a method of
preventing EPM or other complications of S. neurona infec
tion.
Immunogenic amounts of the antigen can be determined

serum antibody complex. The amount of inhibition of mono

clonal antibody binding is measured relative to a control (no

patient serum antibody). The degree of monoclonal antibody

using standard procedures. Brie?y, various concentrations of
a putative speci?c immunoreactive epitope are prepared,

inhibition is a very speci?c test for a particular variety or

strain since it is based on monoclonal antibody binding
speci?city. MAbs can also be used for detection directly in

administered to an animal and the immunological response

cells by IFA.

(e.g., the production of antibodies) of an animal to each
concentration is determined.

A micro-agglutination test can also be used to detect the

The pharmaceutically acceptable carrier can comprise
saline or other suitable carriers (Amon, R. (Ed.) Synthetic

presence of S. neurona in a subject. Brie?y, latex beads (or
red blood cells) are coated With the antigen and mixed With
a sample from the subject, such that antibodies in the tissue
or body ?uids that are speci?cally reactive With the antigen

Vaccines I: 83*92, CRC Press, Inc., Boca Raton, Fla., 1987).
An adjuvant can also be a part of the carrier of the vaccine,

crosslink With the antigen, causing agglutination. The agglu

in Which case it can be selected by standard criteria based on

tinated antigen-antibody complexes form a precipitate, vis

the antigen used, the mode of administration and the subject
(Arnon, R. (Ed.), 1987). Methods of administration can be
by oral or sublingual means, or by injection, depending on
the particular vaccine used and the subject to Whom it is

ible With the naked eye or capable of being detected by a
spectrophotometer. In a modi?cation of the above test,
antibodies speci?cally reactive With the antigen can be
bound to the beads and antigen in the tissue or body ?uid
In addition, as in a typical sandWich assay, the antibody

administered.
It can be appreciated from the above that the vaccine can
be used as a prophylactic or a therapeutic modality. Thus, the

can be bound to a substrate and reacted With the antigen

invention provides methods of preventing or treating S.

20

thereby detected.
Thereafter, a secondary labeled antibody is bound to
epitopes not recogniZed by the ?rst antibody and the sec

25

ondary antibody is detected. Since the present invention
provides S. neurona antigen for the detection of infectious,

Nucleic acid vaccines against S. neurona are also con

templated by the invention. The antigenic agent for use in

S. neurona or previous S. neurona infection other serological

methods such as ?oW cytometry and immunoprecipitation
can also be used as detection methods.

30

In the diagnostic methods taught herein, the antigen can
be bound to a substrate and contacted by a ?uid sample such
as serum, cerebrospinal ?uid, urine, saliva, feces or gastric
juice. This sample can be taken directly from the patient or
in a partially puri?ed form. In this manner, antibodies

neurona infection and the associated diseases by adminis
tering the vaccine to a subject.

the vaccines of the invention can be any nucleic acid, e.g.,
as set forth in the Sequence Listing, that can stimulate an
immune response against, e.g., SnSAG2, SnSAG3 or
SnSAG4 When administered to a subject. Suitable nucleic

acids include those that encode the native proteins of S.
neurona, e.g., SnSAG2, SnSAG3 or SnSAG4 protein or a

speci?c for the antigen (the primary antibody) Will speci?

variant or antigenic peptide fragment thereof, such as, e.g.,
the nucleic acid set forth in the Sequence listing as SEQ ID
NO:23, SEQ ID NO:25 or SEQ ID NO:27. The nucleic acid

cally react With the bound antigen. Thereafter, a secondary

used as a vaccine can be e.g., a naked DNA, or the nucleic

35

antibody bound to, or labeled With, a detectable moiety can

acid can be incorporated in an expression vector as set forth

be added to enhance the detection of the primary antibody.
Generally, the secondary antibody or other ligand Which is
reactive, either speci?cally With a different epitope of the
antigen or nonspeci?c ally With, the ligand or reacted
antibody, Will be selected for its ability to react With multiple
sites on the primary antibody. Thus, for example, several
molecules of the secondary antibody can react With each

herein, e.g., in an Alpha virus vector (see, e.g., Rosenberg,
40

S. A., Immunity 10:281, 1999).
The presence of S. neurona can also be determined by

detecting the presence of a nucleic acid speci?c for S.

45

neurona or the antigens of S. neurona encoded by the nucleic
acids set forth herein. The present invention provides a
method of detecting the presence of S. neurona in a subject,

primary antibody, making the primary antibody more detect

comprising detecting the presence of the nucleic acid encod

able.
The detectable moiety Will alloW visual detection of a
precipitate or a color change, visual detection by micros
copy, or automated detection by spectrometry, radiometric
measurement or the like. Examples of detectable moieties
include ?uorescein and rhodamine (for ?uorescence micros

ing S. neurona. As set forth more fully in the examples
beloW, the speci?city of these sequences for S. neurona can

be determined by conducting a computerized comparison
50

copy), horseradish peroxidase (for either light or electron

microscopy and biochemical detection), biotin-streptavidin
(for light or electron microscopy) and alkaline phosphatase
(for biochemical detection by color change). The detection

55
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The antigen, e.g., a puri?ed antigenic polypeptide frag
be used in the construction of a vaccine comprising an

antigen on an intact S. neurona organism, E. coli or other

strain, or an epitope speci?c to the antigen. The vaccine can

tively, the nucleic acid is detected utiliZing direct hybrid
iZation or by utiliZing a restriction fragment length poly
morphism. For example, the present invention provides a
method of detecting the presence of S. neurona comprising
ascertaining the presence of a nucleotide sequence associ
ated With a restriction endonuclease cleavage site. In addi

ment encoded by the Sequence Listing of this invention can

immunogenic mount of the antigen and a pharmaceutically
acceptable carrier. The vaccine can be the entire antigen, the

The nucleic acid speci?c for S. neurona can be detected

utiliZing a nucleic acid ampli?cation technique, such as
polymerase chain reaction or ligase chain reaction. Altema

methods and moieties used can be selected, for example,
from the list above or other suitable examples by the
standard criteria applied to such selections (HarloW and

Lane, 1988).

With knoWn sequences, catalogued in GenBank, a comput
eriZed database, using the computer programs Word Search
or FASTA of the Genetics Computer Group (Madison, Wis.),
Which search the catalogued nucleotide sequences for simi
larities to the nucleic acid in question.

tion, PCR primers Which hybridize only With nucleic acids
65

speci?c for S. neurona can be utiliZed. The presence of
ampli?cation indicates the presence of S. neurona sequence.
In another embodiment a restriction fragment of a nucleic
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acid sample can be sequenced directly using, techniques

Similar creation of additional restriction sites by nucle

known in the art and described herein and compared to the

otide substitutions at the disclosed mutation sites can be

known unique sequence to detect S. neurona. In a further

readily calculated by reference to the genetic code and a list
of nucleotide sequences recognized by restriction endonu

embodiment, the present invention provides a method of
detecting the presence of S. neurona by selective ampli?
cation by the methods described herein. In yet another
embodiment S. neurona can be detected by directly hybrid

5

changes. Which may be appropriate in at least some
instances.
In general, primers for PCR and LCR are usually about 20

izing the unique sequence With a S. neurona selective

nucleic acid probe. Furthermore, the nucleotide sequence
could be ampli?ed prior to hybridization by the methods

bp in length and the preferable range is from l5i25 bp.

described above.
Alternative probing techniques, such as ligase chain reac

Better ampli?cation is obtained When both primers are the
same length and With roughly the same nucleotide compo
sition. Denaturation of strands usually takes place at about
94.degree. C. and extension from the primers is usually at

tion (LCR), involve the use of mismatch probes, i.e., probes
Which are fully complementary With the target except at the
point of the mutation. The target sequence is then alloWed to

hybridize both With oligonucleotides Which are fully
complementary and have oligonucleotides containing a mis
match, under conditions Which Will distinguish betWeen the
tWo. By manipulating the reaction conditions, it is possible
to obtain hybridization only Where there is full complemen
tarity. If a mismatch is present there is signi?cantly reduced

about 72.degree. C. The annealing temperature varies
according to the sequence under investigation. Examples of
reaction times are: 20 mins denaturing; 35 cycles of 2 min,
1 min, 1 min for annealing, extension and denaturation; and
?nally a 5 min extension step.
20

PCR ampli?cation of speci?c alleles (PASA) is a rapid
method of detecting single-base mutations or polymor
phisms. PASA (also knoWn as allele speci?c ampli?cation)
involves ampli?cation With tWo oligonucleotide primers

25

ciently ampli?ed, While the other allele(s) is poorly ampli

hybridization.
The polymerase chain reaction (PCR) and reverse tran

scriptase PCR are techniques that amplify speci?c nucleic
acid sequences With remarkable e?iciency. Repeated cycles
of denaturation, primer annealing and extension carried out
With polymerase; e.g., a heat stable enzyme Taq polymerase,
leads to exponential increases in the concentration of desired
nucleic acid sequences. Given a knoWledge of the nucleotide
sequence of S. neurona as set forth herein, synthetic oligo
nucleotides can be prepared Which are complementary to
sequences Which ?ank the nucleic acid of interest. Each
oligonucleotide is complementary to one of the tWo strands.
The nucleic acid can be denatured at high temperatures (e.g.,

95.degree. C.) and then reannealed in the presence of a large
molar excess of oligonucleotides. The oligonucleotides,
oriented With their 3' ends pointing toWards each other,
hybridize to opposite strands of the target sequence and

such that one is allele-speci?c. The desired allele is e?i
?ed because it mismatches With a base at or near the 3' end

of the allele-speci?c primer. Thus, PASA or the related
method of PAMSA may be used to speci?cally amplify the
mutation sequences of the invention. Where such ampli?
30

successfully detect a single-base substitution. LCR probes
35

may be combined or multiplexed for simultaneously screen

ing for multiple di?‘erent mutations. Thus, LCR can be
particularly useful Where, as here, multiple mutations are
40

ampli?cation of a nucleic acid segment by more than one
million-fold can be achieved. The resulting nucleic acid may

then be directly sequenced.
In yet another method, PCR may be folloWed by restric

cation is done on S. neurona isolates or samples obtained
from an individual, it can serve as a method of detecting the
presence of S. neurona. As mentioned above, a method

knoWn as ligase chain reaction (LCR) can be used to

prime enzymatic extension along the nucleic acid template.
The end product is then denatured again for another cycle.
After this three-step cycle has been repeated several times,

cleases. Single strand conformational analysis (SSCA)
o?‘ers a relatively quick method of detecting sequence
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predictive of the same disease.
The present invention is more particularly described in the
folloWing examples Which are intended as illustrative only
since numerous modi?cations and variations therein Will be
apparent to those skilled in the art.
EXAMPLES

tion endonuclease digestion With subsequent analysis of the
resultant products. Nucleotide substitutions can result in the
gain or loss of speci?c restriction endonuclease sites. The
gain or loss of a restriction endonuclease recognition site

facilitates the detection of the organism using restriction

Identi?cation and Characterization of SnSAGl
50

Surface biotinylation of extracellular merozoites revealed
only tWo dominant labeled molecules that migrate at about

fragment length polymorphism (RFLP) analysis or by detec

30 kDa and 16 kDa in SDS-PAGE. Analysis of a S. neurona

tion of the presence or absence of a polymorphic restriction
endonuclease site in a PCR product that spans the sequence
of interest.

orthologue of the 31-kDa surface antigen from Sarcocyslis

For RFLP analysis, nucleic acid is obtained, for example

EST database (currently 1800+ sequences) identi?ed an
muris. The sequence of the S. neurona surface antigen gene,
55

designated SnSAGl, is predicted to encode a 276-residue

from the blood, cerebrospinal ?uid, gastric specimen, saliva,

protein With an amino-terminal signal peptide and a car

dental plaque, other bodily ?uids of the subject suspected of

boxy-terminal GPI anchor addition. Antiserum raised
against recombinant SnSAGl recognized a 25-kDa antigen

containing S. neurona, is digested With a restriction endo

nuclease, and subsequently separated on the basis of size by
agarose gel electrophoresis. The Southern blot technique can
then be used to detect, by hybridization With labeled probes,
the products of endonuclease digestion. The patterns

in Western blots of non-reduced S. neurona lysates, consis
60

SnSAGl. Under reducing conditions, SnSAGl migrated
aberrantly at about 30 kDa, similar to What has been
observed in Western blot analyses of reduced T gondii

obtained from the Southern blot can then be compared.
Using such an approach, S. neurona nucleic acid is detected

and their mobility on the gel by determining the number of
bands detected and comparing this pattern to the nucleic acid
from S. neurona.

tent With the molecular Weight predicted for the mature

surface antigens. Immuno?uorescence labeling of SnSAGl
65

during intracellular groWth of S. neurona indicated that the

protein is expressed throughout schizogony. Interestingly, a
?lamentous staining pattern Was observed in intermediate
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schizonts that likely re?ects localization of the surface

BigDye Terminator Cycle Sequencing reaction mix (Perkin

antigen to previously-described invaginations of the sch

Elmer Applied Biosystems). The reactions Were puri?ed

izont surface membrane.

using Centri-Sep spin columns (Princeton Separations), and
the eluted extension products Were resolved and analyzed on
an ABI 310 Genetic Analyzer. Sequence analyses Were

Materials and Methods

conducted With Genetics Computer Group (GCG) softWare
[Devereux, 1984 #1176] and programs available on the

Parasite Culture
S. neurona strain SN3 [Granstrom, 1992 #1600] mero
zoites Were propagated by serial passage in bovine turbinate

National Center for Biotechnology Information (NCBI) Web
site (See, e.g., WWW.ncbi.nlm.nih.gov/) and the Expert Pro
tein Analysis System (ExPASy) server of the SWiss Institute

(BT) cells and maintained in RPMI 1640 medium supple

of Bioinformatics (See, e.g., WWW.expasy.ch/). Multiple

mented With 10% fetal bovine serum, 2 mM sodium pyru

sequence alignments Were performed using Multalin soft
Ware [Corpet, 1988 #2046]. The sequence reported herein
has been deposited into GenBank under accession number

vate, Pen/Strep Fungizone (BioWhittaker, Inc.). Extracellu
lar merozoites Were harvested and puri?ed from disrupted
host cell monolayers by ?ltration through 3.0 pm mem
branes, as described previously for Neaspora caninum

AY032845.

Recombinant SnSAG1 Expression and Generation of Poly

[HoWe, 1997 #1372].

clonal Antiserum

Immunoscreen of S. neurona cDNA Library
Construction and analyses of the cSn.1 S. neurona mero

zoite cDNA library has been described previously [HoWe,

The SnSAG1 open reading frame Without the predicted
20

2001 #1787]. The library Was plaqued for 3 hrs at 420 C. on
XL 1-Blue MRF' E. coli host cells (Stratagene) groWn on

150 mm NZY agar plates. When plaques became visible,
plates Were overlayed With nitrocellulose ?lters previously
soaked in 10 mM isopropyl-[3-D-thiogalactopyranoside

25

Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% TWeen 20), and
blocked in phosphate buffered saline (PBS), 5% dry milk,
30

Antigenic cDNA clones Were identi?ed by screening With
cerebrospinal ?uid (CSF) from a horse that had been natu
rally infected With S. neurona and exhibited a high titer of
intrathecal antibodies against S. neurona in Western blot
analysis. Prior to screening the S. neurona cDNA library, the
CSF Was diluted 1:20 in PBS, 0.1% dry milk, 0.1% normal
goat serum, 0.05% TWeen 20 and incubated for 30 min With

hydrophobic tail Was ampli?ed by PCR from the pSnAg8
cDNA using primers that introduce a NdeI restriction site
prior to base 45 (numbered from the initiation codon) and an
XhoI site after base 743. The ampli?cation product Was

(IPTG) for an additional 3 hr incubation at 370 C. Filters
Were lifted from the plates, Washed With TNT buffer (10 mM

5% normal goat serum, 0.05% TWeen 20.

amino-terminal signal peptide and the carboxyl-terminal

digested With NdeI and XhoI, ligated into NdeI/XhoI-di
gested pET22b expression vector (Novagen), and trans
formed into INVotF' E. coli. The resulting expression plas
mid, designated prSnSAG1, Was transformed into BL21
CodonPlus E. coli (Stratagene), and a clone that expressed
high levels of recombinant SnSAG1 (rSnSAG1) Was
selected for use. The histidine-tagged rSnSAGl Was puri?ed

by nickel-column chromatography according to the manu

facturer’s protocol (Novagen), and monospeci?c polyclonal
antisera Were produced against the puri?ed protein by
35

immunization of a rabbit and rat (Cocalico Biologicals,

Inc.).

After adsorption of potential cross-reactive antibodies, the

Western Blot Analysis
Parasites Were lysed in sodium dodecyl sulfate (SDS)
sample buffer supplemented With protease inhibitor cocktail
(Sigma) and 2% 2-mercaptoethanol, and the lysates Were
separated in 10% or 12% polyacrylamide gels [Laemmli,

diluted CSF solution Was incubated for 1 hr With the cSn.1
?lters. After Washing, ?lters Were incubated for 1 hr With

membranes by semidry electrophoretic transfer in Tris

?lters carrying plaque lifts of a previously-described N.
caninum cDNA library [HoWe, 1999 #1759] to remove
antibodies that Were reactive With E. coli and phage proteins.

goat anti-equine IgG conjugated to horseradish peroxidase
(HRP) (Jackson Immunoresearch Labs, Inc.) diluted to

40

1970 #393]. Proteins Were transferred to nitrocellulose

45

1:10,000. Immuno-reactive phage plaques Were picked With
sterile pipet tips and suspended in 40 pl of SM buffer (50
mM Tris-HCl, pH 7.5, 100 mM NaCl, 8 mM MgSO4, 0.01%

conjugated immunoglobulin G secondary antibody (Jackson

gelatin). The cDNA inserts Were PCR ampli?ed using the T3

and T7 oligonucleotide primers, and the resulting products
Were analyzed by agarose gel electrophoresis. Sequencing
reactions using T3 primer Were conducted on the ampli?ed
cDNAs to provide a preliminary identi?cation of the immu
noreactive clones. Phagemid excision Was performed on
selected cDNA clones, and plasmids Were rescued in SOLR

50

Immunoresearch Labs, Inc.). Blots Were Washed, processed
for chemiluminescence using Supersignal substrate (Pierce
Chemical Company), and exposed to ?lm.

Biotinylation of Surface Proteins and Precipitation With

Immobilized Streptavidin
55

cells according to the manufacturer’s protocol (Stratagene).

Approximately 3><107 freshly harvested merozoites Were
resuspended in 1 ml cold PBS (pH 7.8). Sulfo-N-hydroxy
succinimide-biotin (Pierce) Was added to a concentration of

S. neurona EST Database Searches and Sequence Analyses
S. neurona homologues to previously-characterized coc
cidian surface antigens Were identi?ed in the S. neurona

glycine buffer (pH 8.3). Membranes Were blocked With PBS
containing 5% nonfat dry milk, 5% goat serum, and 0.05%
TWeen 20, and then incubated for 1 hr With primary anti
body. After Washing, membranes Were incubated With HRP

60

0.5 mg/ml and incubated at room temperature for 30 min.
The labeled parasites Were Washed tWice With 5 ml of PBS
and stored at —200 C.

clustered EST database (See, e.g., paradb.cis.upenn.edu/

The labeled parasite pellet Was lysed With 1 ml radioim

sarco/index.html) using the BLAST (basic local alignment

munoprecipitation assay (RIPA) buffer (50 mM Tris [pH

search tool) set of programs [Altschul, 1990 #616]. At the

7.5], 1% Triton X-100, 0.5% sodium deoxycholate, 0.2%
SDS, 100 mM NaCl, 5 mM EDTA) supplemented With

time the database Was searched, it contained 686 consensus
sequences that had been generated from 1883 S. neurona
ESTs. Selected cDNAs Were obtained from the archived

collection of EST clones and sequenced using ABI Prism

65

RNase, DNase, protease inhibitor cocktail, and the sample
Was centrifuged at 16,000><g to remove the insoluble frac
tion. The soluble proteins Were incubated With UltraLink
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immobilized streptavidin (Pierce), and the precipitated

SWiss Institute of Bioinformatics). A single N-glycosylation

biotin-labeled protein fraction Was analyzed by Western

site Was predicted at residues 140*143. Removal of the
N-terminal and C-terminal signal sequences results in a
mature protein of 242 amino acids that has a predicted

blotting, as described above.

Immuno?uorescent Labeling of Extracellular and Intracel

molecular Weight of 24.2 kDa before any potential post

lular Parasites
For detection of SnSAGl on extracellular parasites and in

translational modi?cations (e.g., glycolipid anchor addition,

glycosylation).

trails deposited by gliding parasites, freshly lysed meroZoi

To identify homology to previously characteriZed

tes Were suspended in fresh RPMI 1640 and incubated on

sequences, BLAST searches [Altschul, 1990 #616] of the

poly-L-lysine-coated slides for approximately 30 min.

non-redundant GenBank databases Were conducted With the

Slides Were Washed With PBS, and the parasites Were ?xed

SnAgI.8 coding sequence as the query. These searches
revealed a statistically signi?cant similarity to the 31 kDa

in 2.5% formalin-PBS containing 0.01% glutaraldehyde. For
detection of SnSAGl on intracellular parasites, meroZoites

major surface antigen of Sarcocyslis muris [Eschenbacher,

Were inoculated onto BT cells groWn on LabTek chamber

1992 #1767] and a less signi?cant but recogniZable simi
larity to several SAG2-related surface antigens from T

slides (Nunc). At 24 hr, 48 hr, or 72 hr post-inoculation, the
cells Were ?xed in 2.5% formalin-PBS/0.01% glutaralde

gondii [Lekutis, 2000 #2049]. (FIG. 2). In conjunction With

hyde and permeabliZed With 0.2% TritonX-100. After incu
bation With primary antibody, the slides Were rinsed, then
incubated With ?uorescein isothiocyanate (FITC)-conju

gated goat anti-rabbit IgG (Jackson Immunoresearch Labs,
Inc.). The slides Were mounted in Vectashield With DAPI

the Western blot analysis and the predictions of a signal
peptide and a GPI-anchor addition, these results suggested

that the gene represented by the SnAgI.8 and SnAgI.9
20

cDNAs encodes an immunodominant surface antigen of S.

25

neurona; consequently, We tentatively designated this pro
tein SnSAGl, folloWing the genetic nomenclature that is
utiliZed for the related apicomplexan parasites T gondii and
N. caninum [Sibley, 1991 #13; HoWe, 1999 #1759].
The sequence analysis for SnGAG2, SnGAG3, and

(Vector Laboratories, Inc.) and examined With a Zeiss axio

scope equipped for epi?uorescence microscopy.
Results

SnGAG4 as Well as for the SnGF Cluster sequences pro

Isolation and Analysis of Immunoreactive cDNA Clones
A primary screen of the cSn.1 cDNA library identi?ed
multiple immunoreactive phage plaques, and a total of 25
plaques Were isolated and resuspended in SM buffer. Ampli
?cation of the cDNA inserts With T3 and T7 oligonucle
otides revealed that 22 of the phage clones had similar

vided by the invention and set forth herein have been derived
in a fashion similar to that set forth above for SnGAGl.
30

vaccines and/or antigen/antibody kits for prevention and
diagnosis of Sarcocystis neurona infection. One preferred

lengths of approximately 1500 base pairs (bp), and sequence
analysis using T3 primer indicated that these 22 cDNAs
represent the same gene. A secondary screen Was performed
on ?ve of the selected cDNAs, and tWo highly reactive

These novel nucleotide sequences and protein sequences of
Sarcocyslis neurona can be utiliZed in the production of

embodiment of the invention is a vaccine comprised of an

alpha virus expression vector and nucleic acid selected from
35

phage clones, designated SnAgI.8 and SnAgI.9, Were chosen
for further analyses.

the nucleic acid sequences disclosed herein.
Identi?cation of S. neurona Surface Antigens and
Expression as Recombinant Proteins

To obtain a preliminary identi?cation of the parasite

protein encoded by the selected cDNAs, the SnAgI.9 clone

40

Was used to a?inity purify antibodies that bind the antigen
expressed by this clone, and the eluted antibodies Were used

Analysis of the S. neurona EST database revealed four

paralogous proteins that are homologous to the SAG and
SRS surface antigens of Toxoplasma gondii. Each S. neu

to probe a Western blot of S. neurona meroZoite lysate. As

rona gene Was predicted to encode a protein that possessed

shoWn in FIG. 1, the puri?ed antibodies reacted With an

an amino-terminal signal peptide and a carboxyl-terminal

approximately 31-kDa antigen in reduced S. neurona lysate.

45

Furthermore, the antigen revealed by the phage-puri?ed
antibodies comigrated With a protein that is recognized by

SAGs and their probable surface display on meroZoites, the
four S. neurona proteins Were designated SnSAGl,

equine or rabbit antisera against S. neurona as the major

immunodominant antigen of this parasite (FIG. 1, lanes 2
and 3). This result implies that the 22 matching cDNA clones
isolated during the library screen and represented by
SnAgI.8 and SnAgI.9 encode the immunodominant antigen

SnSAG2, SnSAG3, and SnSAG4. The four putative surface
50

Full-length sequence analysis of SnAgI.8 revealed a

virtually identical to SnAgI.8, although its 3' untranslated
region (UTR) Was approximately 160 nucleotides longer due
to an alternative polyadenylation site. A hydrophobicity plot
of the encoded protein shoWed hydrophobic domains at both
termini, Which correspond to a predicted signal peptide at
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[Nielsen, 1997 #2047], and the most likely GPI transami
dase cleavage site is predicted to be at Ala247-Asn248 (DGPI;

polyclonal antisera Were used in Western blot analysis of
reduced (With 2-mercaptoethanol) S. neurona lysate to
reveal each of the SnSAGs (See, FIG. 3). The mature forms
of native SnSAGl and SnSAG4 are predicted to be approxi

mately 24 kDa, but these antigens co-migrated at approxi
mately 30*32 kDa and correspond to the immunodominant
antigen Sn30 that has been described previously (See, FIG.
60

3) (Granstrom et al., 1993; Liang et al., 1998). SnSAGl has
also been identi?ed by others as a major surface antigen

matching the immunodominant Sn30 band (Ellison et al.,
2002), but it is apparent that SnSAG4 likely contributes to
the antibody reactivity at this molecular Weight. The mature

the amino terminus and a GPI anchor addition sequence at

the carboxyl terminus (data not shoWn). The signal peptide
cleavage is predicted to occur at Alals-Argl6 (SignalP;

antigens Were each expressed as a recombinant protein in E.
coli, and these Were used to immuniZe rabbits and rats for

monospeci?c polyclonal antisera production. The resulting

of S. neurona.

cDNA insert of 1493 nucleotides, With an open reading
frame (ORF) that encodes a 276 amino acid protein.
Sequence analysis of SnAgI.9 indicated that this clone Was

glycolipid anchor site, consistent With the proteins being
surface antigens. Because of their similarity to Toxoplasma

65

form of SnSAG2 is predicted to be about 12 kDa, but this
antigen migrated at approximately 18*19 kDa and corre
sponds to the previously described immunodominant Sn16
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antigen (See, FIG. 3) (Granstrom et al., 1993; Liang et al.,

can be added to each Well in high-binding capacity ELISA

1998). Mature SnSAG3 is predicted to be 23 kDa, but
migrated at about 28 kDa (See, FIG. 3). The aberrant
migration of the SnSAGs under reducing conditions is a
characteristic that has been observed previously for the
surface antigens of both T gondii (Burg et al., 1988;
Cesbron-DelauW et al., 1994) and N. caninum (HoWe et al.,
1998). Importantly, the Western blot experiments demon

plates (Corning). After overnight incubation at 4C, Wells can
be blocked by incubation for 1 hr With PBS containing 5%
normal goat serum, 0.1% TWeen 20, and 0.5% non-fat dry
milk. The primary sera or CSF samples can be diluted in PB
S/0.1% TWeen 20 and incubated in the Wells for 2 hrs at
room temperature. The Wells can then be Washed 4 times
With PBS/0.1% TWeen 20 and incubated With horseradish

peroxidase (HRP)-conjugated anti-equine immunoglobulin
secondary antibody (Jackson Immunoresearch Labs, Inc.).

strated that the recombinant forms of the SnSAGs are

recogniZed by antibodies from S. neurona-infected horses.
There is strong concordance betWeen antibody recognition
of recombinant SnSAGl (rSnSAGl) and standard Western

The Wells can again be Washed With PBS/TWeen, and the
presence of bound secondary reagent can be detected by

blot analysis of complete parasite antigen (i.e., S. neurona

addition of the chromogenic substrate O-phenylenediamine

meroZoite lysate). Similar results Were obtained With rSn

(Sigma-Aldrich) (HarloW and Lane, 1988). The optical

SAG2, rSnSAG3, and rSnSAG4. These data demonstrate
the utility of using the rSnSAGs in ELISA formats to
monitor antibody responses in S. neurona-infected horses.

density at 490 nm (OD490) of the reactions can be read in

an EMax microplate reader (Molecular Devices), and results
can be analyZed With SOFTmax PRO 4.0 computer soft
Ware.

EnZyme-Linked Immunosorbent Assays (ELISAs)
Based on Recombinant S. neurona Surface

The foregoing descriptions of novel and preferred
20

Antigens (rSnSAGs)

embodiments of the invention have been presented for
purposes of illustration and description. The descriptions are
not intended to be exhaustive or to limit the invention to the

The rSnSAGs expressed in E. coli have been shoWn in
Western blots to be recogniZed by equine antibodies; con
sequently, these recombinant antigens can be utiliZed as the
key reagents for developing ELISAs based on single S.
neurona antigens. Given the teachings set forth herein and

precise form disclosed. Obvious modi?cations or variations

are possible in light of the above testing. The embodiment
25

the principles of the invention and its practical application to
thereby enable one of ordinary skill in the art to utiliZe the
invention in various embodiments and With various modi

utiliZing methods knoWn in the art, an ELISA test can be

developed for each of the four rSnSAGs that have been
identi?ed by the invention, and all four assays can be
optimiZed and evaluated in detail, as described beloW.

Was chosen and described to provide the best illustration of

30

?cations as are suited to the particular use contemplated. All
such modi?cations and variations are Within the scope of the

invention as determined by the claims made in this appli
cation When interpreted in accordance With the breadth to

Expression and Puri?cation of Recombinant SnSAGs.

Which they are fairly, legally and equitably entitled.

To produce highly puri?ed recombinant forms of the
SnSAGs, the genes for each antigen have been cloned into
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